

Silencing circZFR Inhibits the Proliferation, Migration and Invasion of Human Renal Carcinoma Cells by Regulating miR-206 [Retraction]

Wang M, Gao Y, Liu J. *Onco Targets Ther.* 2019;12:7537–7550.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised regarding similarities of the western blot images within the article to those found in other articles. Further analysis found that several regions within the western blot images appeared to have been duplicated. In addition, several regions within the western blot images appeared to have been duplicated with those from other articles, which included:

- Qian et al. Salidroside alleviates high-glucose-induced injury in retinal pigment epithelial cell line ARPE-19 by down-regulation of miR-138, *RNA Biology* 16:10 1461–1470 2019 (<https://doi.org/10.1080/15476286.2019.1637696>) RETRACTED
- Zhang et al. Silencing UNC5B antisense lncRNA 1 represses growth and metastasis of human Colon cancer cells via raising miR-622, *Artificial Cells, Nanomedicine, and Biotechnology* 48:1 60–67 2019 (<https://doi.org/10.1080/21691401.2019.1699809>) RETRACTED

The authors responded to our initial queries but were unable to provide a satisfactory explanation for the similarities nor were they able to provide adequate original western blot data or verify the findings as reported. The Editor requested for the article to be retracted and the authors were notified of this.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.S374910>

OncoTargets and Therapy 2022;15:539

539

Received: 16 May 2022
Accepted: 16 May 2022
Published: 18 May 2022



© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).